期刊文献+

奥美沙坦酯片在健康人体内的药动学 被引量:4

Pharmacokinetics of olmesartan medoxomil tablets in healthy volunteers
下载PDF
导出
摘要 目的:研究奥美沙坦酯片在健康人体内的药动学。方法:10名健康男性志愿者单剂量口服20 mg奥美沙坦酯片,采用HPLC荧光检测法测定血浆中奥美沙坦浓度,并计算药动学参数。结果:健康志愿者单剂量口服奥美沙坦酯片后的主要药动学参数为:cmax(526.88±75.74)ng/mL,tmax(2.05±0.37)h,t1/2(12.68±2.37)h,MRT(13.86±3.51)h,Cl/F(4.66±0.67)L/h,AUC0-48(3 990.43±679.47)ng.h.mL^-1,AUC0-∞(4 367.95±602.53)ng.h.mL^-1。结论:健康志愿者口服奥美沙坦酯片后吸收迅速,主要药动学参数与国内外文献报道值基本一致。 Objective:To study the pharmacokinetics of olmesartan medoxomil tablets in Chinese healthy volunteers.Methods:Ten healthy male volunteers were given a single oral dose of 20 mg olmesartan medoxomil tablet.Plasma concentrations of olmesartan were determined by HPLC method with fluorescence detection.Results:The main pharmacokinetic parameters were as follows: cmax(526.88±75.74) ng/mL,tmax(2.05±0.37) h,t1/2(12.68±2.37) h,MRT(13.86±3.51) h,Cl/F(4.66±0.67) L/h,AUC0-48(3 990.43±679.47) ng·h·mL^-1 and AUC0-∞(4 367.95±602.53)ng·h·mL^-1 .Conclusion:Olmesartan medoxomil can be rapidly absorbed after oral administration. The main pharmacokinetic parameters are consistent with the values reported in literature.
出处 《药学服务与研究》 CAS CSCD 2009年第5期367-369,共3页 Pharmaceutical Care and Research
关键词 奥美沙坦 色谱法 高压液相 药代动力学 olmesartan chromatography high pressure liquid pharmacokinetics
  • 相关文献

参考文献4

二级参考文献20

  • 1张小丽,于洋,侯艳宁,赵怀清.人血浆中奥美沙坦的HPLC-MS/MS测定[J].中国医药工业杂志,2006,37(10):697-699. 被引量:5
  • 2于洋,侯艳宁,刘建芳,王金.固相萃取结合HPLC-MS测定人血浆中奥美沙坦的药物质量浓度[J].中国药学杂志,2006,41(20):1592-1593. 被引量:7
  • 3[3]Gillis J C, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetics properties and therapeutic use in the management of hypertension. Drugs,1997,54(6):885
  • 4[4]Vachharajani N N, Shyu W C, Chando T J et al. Oral bioavailability and disposition characteristics of irhesartan, an angiotension antagonist, in healthy volunteers. J Clin Pharmacol, 1998,38:702
  • 5Warner GT, Jarvis B. Olmesartan medoxomil [J].Drugs, 2002,62 (9): 1345~ 1353.
  • 6Mizuno M,Sada T,Ikeda M et al. Pharmacology of CS-866,a novel nonpeptide angiotension Ⅱ receptor antagonist[J]. Eur J Pharmacol, 1995,285 (2): 181~188.
  • 7Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil ,an angiotension Ⅱ type AT1 receptor antagonist[J]. J Hypertens,2001,19(Suppl 1) :S3~S14.
  • 8Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotension Ⅱ receptor blocker,in health subjects [J]. J Clin Pharmacol, 2001,41 (5):515~527.
  • 9Mizuno M,Sada T,Ikeda M et al. Effects of CS-866 on hypertensive nephropathy in SHR and DOCA rats [J]. Jpn J Pharmacol, 1997,73(Suppl 1) : 135.
  • 10Von Bergmann K, Laeis P, Puchler K. Olmesartan medoxomil:Influence of age,renal and hepatic function on the pharmacokinetics of Olmesartan medoxomil[J]. J Hypertens, 2001,19 (Suppl 1 ): S33~S40.

共引文献9

同被引文献66

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部